Burrows Scott L — SEC insider filings
SEC reporting owner CIK 1853327. 25 insider filings on record with FilingPulse; latest filed 2026-10-02.
Transaction summary — filings shown
Covers all 25 filings on record, filed 2021-04-05 to 2026-10-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 36 legs across 16 filings — 163,115 shares, $10,244,496 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 33.
- Largest priced transaction: sale of 18,232 shares @ $89.35 ($1,629,029) in Spyre Therapeutics, Inc., filed 2026-09-03.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | 16 | — | 28 legs · 147,691 sh · $9,945,934 | 25 |
| Arcutis Biotherapeutics, Inc. (ARQT) | Chief Financial Officer | 9 | — | 8 legs · 15,424 sh · $298,563 | 8 |
Insider filings — Burrows Scott L
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-02 | 4 | Spyre Therapeutics, Inc. (SYRE) | Option exercise (M): 17,500 @ $14.50 · Sale (S): 17,500 @ $89.89 · Option exercise (M): 7,500 @ $14.50 · Sale (S): 600 @ $89.07 · Sale (S): 1,500 @ $90.27 · Sale (S): 2,100 @ $91.92 · +4 more | EDGAR |
| 2026-09-03 | 4 | Spyre Therapeutics, Inc. (SYRE) | Option exercise (M): 7,500 @ $14.50 · Sale (S): 900 @ $86.25 · Sale (S): 4,384 @ $87.11 · Sale (S): 2,016 @ $88.03 · Sale (S): 200 @ $89.04 · Sale (S): 18,232 @ $89.35 · +1 more | EDGAR |
| 2026-08-05 | 4 | Spyre Therapeutics, Inc. (SYRE) | Option exercise (M): 7,500 @ $14.50 · Sale (S): 5,100 @ $95.21 · Sale (S): 2,300 @ $96.30 · Sale (S): 100 @ $97.10 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Spyre Therapeutics, Inc. (SYRE) | Option exercise (M): 7,500 @ $14.50 · Sale (S): 5,775 @ $87.55 · Sale (S): 1,725 @ $88.37 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | Spyre Therapeutics, Inc. (SYRE) | Option exercise (M): 15,000 @ $14.50 · Sale (S): 5,000 @ $87.12 · Sale (S): 10,000 @ $87.14 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Spyre Therapeutics, Inc. (SYRE) | Option exercise (M): 7,500 @ $14.50 · Sale (S): 1,801 @ $69.75 · Sale (S): 2,599 @ $70.77 · Sale (S): 3,100 @ $72.06 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Spyre Therapeutics, Inc. (SYRE) | Option exercise (M): 12,500 @ $14.50 · Sale (S): 12,500 @ $71.37 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Spyre Therapeutics, Inc. (SYRE) | Option exercise (M): 7,500 @ $14.50 · Sale (S): 6,200 @ $49.21 · Sale (S): 1,300 @ $49.98 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Spyre Therapeutics, Inc. (SYRE) | Option exercise (M): 2,500 @ $14.50 · Sale (S): 2,300 @ $40.56 · Sale (S): 200 @ $41.66 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2025-09-03 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 18,428 @ $16.26 | EDGAR |
| 2025-01-17 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 95,500 (derivative) @ $0 | EDGAR |
| 2024-09-05 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 18,531 @ $28.17 | EDGAR |
| 2024-02-02 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2023-12-22 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 134,953 @ $0 | EDGAR |
| 2023-09-05 | 4 | Aeglea BioTherapeutics, Inc. (AGLE) | Grant/award (A): 10,121,441 (derivative) @ $0 | EDGAR |
| 2023-03-08 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 291 @ $15.26 | EDGAR |
| 2023-03-06 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 21,000 @ $0 · Grant/award (A): 55,800 (derivative) @ $0 | EDGAR |
| 2023-03-02 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 416 @ $16.17 · Sale (S): 1,416 @ $15.82 · Sale (S): 18 @ $16.52 | EDGAR |
| 2022-09-20 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Option exercise (M): 5,000 @ $1.68 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2022-03-07 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 13,300 @ $0 · Sale (S): 293 @ $16.86 · Sale (S): 10 @ $16.44 · Grant/award (A): 35,300 (derivative) @ $0 | EDGAR |
| 2022-03-03 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 420 @ $17.75 | EDGAR |
| 2022-01-04 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 55,704 (derivative) @ $0 | EDGAR |
| 2021-12-28 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 12,560 @ $20.07 | EDGAR |
| 2021-04-05 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-04-01 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1853327 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs